Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Roundhill Innov-100 0DTE Covered Call Strat ETF (QDTE) vs ResMed Inc. (RMD) Price & Performance

Roundhill Innov-100 0DTE Covered Call Strat ETFTrade
ResMed Inc.Trade

Price performance (Past 24H)

Key statistics

Roundhill Innov-100 0DTE Covered Call Strat ETF vs ResMed Inc. — how do they compare? Roundhill Innov-100 0DTE Covered Call Strat ETF trades at $28.68, while ResMed Inc. trades at $219.5 (market cap $31.89B). The key difference: ResMed Inc. pays a 1.19% dividend while Roundhill Innov-100 0DTE Covered Call Strat ETF pays none, and ResMed Inc. is trading nearer its 52-week high, Roundhill Innov-100 0DTE Covered Call Strat ETF nearer its low. Which is the better fit depends on your goals.

QDTERMD
Sector
Income / Options OverlayHealth
52-Week High
$36.60$283.28
52-Week Low
$26.85$182.82
Market Cap
$31.89B
Enterprise Value
$31.24B
Dividend Yield
1.19%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Roundhill Innov-100 0DTE Covered Call Strat ETF

QDTE trades at $28.86 with minimal daily movement (+0.07%). The ETF shows bearish technical signals with selling pressure outweighing buying signals 12-4. Recent news highlights concerns about the fund's sustainability as volatility declines and distributions are funded by return of capital, causing NAV erosion. The fund's 0.97% expense ratio consumes significant portions of its weekly payouts.

The outlook remains cautious given structural concerns about the fund's distribution model. While weekly income appeals to investors, the erosion of net asset value and dependence on return of capital present significant risks. Analyst sentiment has turned negative with recent downgrades citing underperformance in bull markets and unsustainable yield mechanics.

ResMed Inc.

ResMed (RMD) trades at $221.05, down 3.2% amid a bearish technical signal, though it holds above key support at $218. The company reported strong Q4 2026 results with EPS of $2.95 beating estimates, and revenue grew 9% to a record $1.5 billion. However, weaker fiscal 2027 revenue guidance has pressured the stock. Fundamentals remain solid with a 26.94% net income margin and robust cash flow from operations of $1.75 billion in 2025.

The outlook is mixed; strong profitability and consistent earnings beats support upside toward the $235.70 consensus price target, but near-term sentiment is cautious due to the soft sales forecast and ongoing legal investigations. Key risks include competitive pressures and execution on guidance. Institutional buying by firms like HSBC and Canada Pension Plan provides confidence in long-term value.

Returns comparison

Trailing returns across standard periods

About Roundhill Innov-100 0DTE Covered Call Strat ETF

QDTE is an actively managed ETF that seeks to generate income through a covered call strategy on the NASDAQ 100. It primarily holds a portfolio of U.S. government securities and sells 0-DTE (zero days to expiration) index call options on the NASDAQ 100. This highly tactical strategy aims to maximize option premium capture by exploiting the rapid time decay of options expiring on the same day, which provides enhanced income but also exposes the fund to significant volatility and risks associated with daily options settlement.

Read more on QDTE

About ResMed Inc.

ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.

Read more on RMD